Document is current
Any future updates will be listed below
-
Authors
Bahrami, Hashmat Sayed Zohori
Jørgensen, Peter Godsk
Hove, Jens Dahlgaard
Dixen, Ulrik
Rasmussen, Line Jee Hartmann
Eugen-Olsen, Jesper
Rossing, Peter
Jensen, Magnus T.
-
Funding
Funding for this research was provided by:
Copenhagen University
- License Information
-
More Information
Article History
Received: 21 August 2025
Accepted: 30 December 2025
First Online: 3 February 2026
Declarations
:
: P.G.J. reports support for attending two meetings from Medtronic. J.D.H. reports receiving honoraria for lectures from Novo Nordisk and support for attending two meetings from Novo Nordisk and AstraZeneca. J.E.O. is the Chief Scientific Officer and shareholder in ViroGates A/S and is named as an inventor on patents using suPAR. Copenhagen University Hospital Hvidovre, Denmark, owns the patents. No patents are included in this manuscript. P.R. report grants to his institution from Astra Zeneca, Bayer, and Novo Nordisk; has received honoraria and consulting fees to his institution from Abbott, Astellas, Astra Zeneca, Bayer, Boehringer Ingelheim, Eli Lilly, Gilead, Novo Nordisk, and Sanofi. M.T.J. is the chief executive officer of Steno Diabetes Center Copenhagen, a public hospital funded through a partnership between the Capital Region of Denmark and the Novo Nordisk Foundation. All other authors have declared no conflict of interest.
